Condition: FSGS · Sponsor: Dimerix Bioscience Pty Ltd
DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an ARB. Given the rarity of the disease and the similarities between adults and pediatric patients with FSGS, Dimerix will also investigate the efficacy and safety of DMX 200 in adolescents aged 12 to 17 years. The double-blind period will be followed by an open-label extension (OLE) which aims to assess the long-term efficacy and safety of DMX 200 for up to 2 additional years.
This description comes directly from the study's public registry record.
David Fuller · +61 1300 813 321 · ACTION3@dimerix.com
Alisha Smith · +61 1300 813 321 · ACTION3@dimerix.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Active Not Recruiting |
| Phoenix Children's Hospital | Phoenix, Arizona, United States | Recruiting |
| Arizona Kidney Disease and Hypertension Center | Phoenix, Arizona, United States | Active Not Recruiting |
| Loma Linda University Medical Center | Loma Linda, California, United States | Active Not Recruiting |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| University of California, Los Angeles | Los Angeles, California, United States | Recruiting |
| Amicis Research Centre | Northridge, California, United States | Active Not Recruiting |
| Northridge Clinical Research Inc. | Northridge, California, United States | Active Not Recruiting |
| Kaiser Permanente | Oakland, California, United States | Recruiting |
| University of California Davis Health System | Sacramento, California, United States | Recruiting |
| Scripps Health | San Diego, California, United States | Active Not Recruiting |
| Stanford Hospital and Clinic | Stanford, California, United States | Recruiting |
+ 208 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05183646